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ABSTRACT
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)
are associated with high morbidity and mortality. More in vitro, in vivo, and clinical data
suggest that vancomycin (VAN) or daptomycin
(DAP) combination therapy with b-lactams (BL)
improves outcomes of MRSA infections. We
hypothesize that BL combination with VAN or
DAP would reduce the odds of clinical failure
compared to VAN or DAP monotherapy.
Methods: A retrospective cohort study of adult
patients C 18 years treated with VAN or DAP for
MRSA BSI from 2006 to 2019 at Detroit Medical
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Center. Combination therapy (CT) was defined
as VAN or DAP plus any BL for C 24 h within
72 h of index culture. Monotherapy (MT) was
defined as C 72 h VAN or DAP within 72 h of
index culture and no BL for C 24 h up to 7 days
following VAN/DAP initiation. Primary outcome was composite endpoint of clinical failure
defined as: (1) 30-day mortality, (2) 60-day
recurrence, or (3) persistent bacteremia (PB). PB
was defined as bacteremia [ 5 days. Multivariable logistic regression was used to evaluate the
association between CT and the primary
outcome.
Results: Overall, 597 patients were included in
this analysis, 153 in the MT group and 444 in
the CT group. CT was independently associated
with reduced odds of clinical failure (adjusted
odds ratio, 0.523; 95% confidence interval,
0.348–0.787). The composite endpoint was
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driven by 60-day recurrence and PB but not
30-day mortality. There were no difference in
adverse events including nephrotoxicity
between the two study arms.
Conclusions: In hospitalized adults with MRSA
BSI, CT with any BL was independently associated with improved clinical outcomes and may
ultimately be selected as preferred therapy.
Keywords: b-lactams;
infections; Vancomycin

Gram-positive

Key Summary Points
Combination therapy was independently
associated with reduced odds of clinical
failure in methicillin-resistant
Staphylococcus aureus bloodstream
infections.
The composite endpoint of clinical failure
was driven by 60-day recurrence and
persistent bacteremia but not 30-day
mortality.
Time to bacterial clearance was shorter in
patients managed with combination
therapy compared to monotherapy.

BACKGROUND
Methicillin-resistant
Staphylococcus
aureus
(MRSA) is a major public health concern causing serious community and health-care-associated infections annually [1–3]. Mortality rates
associated with MRSA bloodstream infections
(BSI) can be as high as 57% [3]. For decades,
vancomycin (VAN) has been the mainstay for
the management of MRSA BSI despite complex
dosing strategies, nephrotoxicity risk, and
slower bactericidal rate [4]. Daptomycin (DAP)
is an alternative agent that offers solutions to
VAN pitfalls; however; clinical outcomes for
DAP treated patients, especially with Food and
Drug Administration (FDA)-approved doses, are
not superior to VAN plus gentamicin [5]. Furthermore, some S. aureus mutations encode DAP

resistance and permit enhanced survival characteristics while on DAP treatment [6]. Interestingly, none of the novel agents for MRSA
have been shown to be superior to VAN for
MRSA BSI [5, 7].
Combination therapy (CT) with an active blactam (BL) early in the course of MRSA BSI has
been suggested as a possible treatment strategy
due to observed synergy between glycopeptides
and BLs [8–17]. This phenomenon has been
termed the ‘‘see-saw’’ effect; where, in the presence of glycopeptide or lipoglycopeptide, the
susceptibility to BLs improves [18–21]. Additionally, this strategy achieves higher bactericidal activity, enables use of lower VAN or DAP
doses in vitro and may even allow de-escalation
to one agent [13, 17, 22, 23]. This approach had
been utilized for the clinical management of
MRSA BSI, particularly if adopted early in therapy [8–11, 16, 17, 22, 24–26]. While it had been
quite promising with regards to faster microbiological eradication, the impact on other clinical outcomes, particularly mortality, had been
underwhelming due to the scarcity of quality
clinical evidence [8–11, 15, 16, 25, 27]. On a
more sobering note, VAN CT with some BL
agents, specifically flucloxacillin and piperacillin-tazobactam, had been associated with an
increased risk of acute kidney injury (AKI)
[9, 15, 28, 29]. We sought to determine whether
CT improves clinical outcomes and safety
compared to VAN or DAP monotherapy (MT) in
patients with MRSA BSI.

METHODS
Study Design and Population
This was a retrospective cohort study at the
Detroit Medical Center (DMC) between 2006
and 2019. The DMC is a single large healthsystem of eight hospitals including six centered
in midtown Detroit. Patients were screened and
eligible for inclusion upon meeting the following criteria: (1) age C 18 years; (2) MRSA-positive blood culture meeting Centers for Disease
Control and Prevention criteria for BSI [30], and
(3) treated with VAN or DAP within 72 h of
index culture for C 72 h. Patients were classified
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in the MT group if they did not receive any BL
for C 24 h up to 7 days following VAN/DAP
initiation. Patients were in the CT group if they
received BL for C 24 h within 72 h after VAN/
DAP initiation. Patients were excluded if they
(1) experienced polymicrobial BSI, (2) did not
have follow-up blood cultures, (3) a second
MRSA BSI episode \ 90 days of first episode, (4)
cleared their bacteremia prior to MT or CT initiation, or (5) switched to ceftaroline C 72 h
following MT or CT (Fig. 1). The study was
reviewed and approved by the Wayne State
University Human Investigational Review Board
and the DMC Research Review Committee.

Data Collection and Study Definitions

Fig. 1 Patient enrollment and selection. Exclusion criteria:
(1) experienced polymicrobial BSI, (2) did not have followup blood cultures, (3) a second MRSA BSI episode. BSI

blood stream infections, DAP daptomycin, VAN Vancomycin, MRSA methicillin-resistant Staphylococcal aureus

Demographics, comorbid conditions, laboratory, clinical and treatment data, infectious
disease consult, and the pursuit of source control were extracted from the electronic medical
record and entered into REDCap (Research
Electronic Data Capture, Vanderbilt Univeristy),
an electronic data capture tool hosted at Wayne
State University [31]. Blood cultures were processed at the DMC microbiology laboratories
according to standard procedures. MicroScan
(Siemans Healthcare Diagnostics), Phoenix
(BD), or Vitek2 (bioMerieux) were used for
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bacterial identification and antimicrobial susceptibility testing. The source of BSI was determined
based
on
clinical
notes
and
microbiological/diagnostic reports. Infective
endocarditis was defined according to the
modified Duke criteria [32]. BSI was classified as
hospital-acquired if the index blood culture was
obtained C 48 h after hospital admission. The
Charlson Comorbidity Index (CCI) was used to
measure the degree of patient comorbidity [33].
The severity of illness was quantified using the
Acute Physiology and Chronic Health evaluation II (APACHE II) score at BSI onset [34].
Outcome
The primary outcome was composite failure
defined as (1) 30-day mortality, (2) 60-day
recurrence, or (3) persistent BSI. Recurrence was
defined as the development of recurrent positive culture after apparent clinical cure within
90 days of discharge. Persistent BSI was defined
as BSI C 5 days [35]. All time points were measured from the index MRSA blood culture. Secondary outcomes of interest included the
individual component of the composite outcome, nephrotoxicity, hospital readmission,
length of stay and other safety outcomes.
Nephrotoxicity was defined as an increase in
serum creatinine (0.5 mg/dl or C 50% increase
from baseline, whichever was greater). Other
safety outcomes included thrombocytopenia,
rhabdomyolysis and Clostridioides difficile-associated diarrhea.
Statstical Analysis
Demographics were evaluated using descriptive
statistics where nominal data were reported as
percentages and frequencies, and continuous
data were reported as medians and interquartile
ranges (IQR). Categorical variables between the
success and failure group were compared by the
Chi squared or Fisher’s exact tests, and continuous variables were compared by the Student’s
t test or Mann–Whitney U test, as appropriate.
Multivariable logistic regression was performed
to examine the independent association
between CT and clinical failure while adjusting

for confounding variables. CT and monotherapy, alone with all baseline variables associated
with clinical failure in the bivariate analysis at
P \ 0.2 were included in the logistic regression
models simultaneously and removed using a
backward stepwise approach. Variables that
were not deemed to be independent were not
included. The variance inflation factor was used
to assess the multicollinearity of candidate
regression. Values in the range of 1–5 were
deemed to be appropriate. Covariates were
retained in the model if the P value for the
likelihood ratio test for their removal was \ 0.1.
Model fit was assessed with the Hosmer–Lemeshow goodness of fit test. All tests
were two tailed with P values B 0.5 to be considered significant. IBM SPSS software, ve.6.0
(SPSS, Chicago, IL, USA) was used for all
calculations.

RESULTS
Study Population
Our database identified 1942 patients in whom
MRSA BSI and VAN/DAP had been completed
for C 72 h. Of these patients, 1345 cases were
excluded (Fig. 1). Overall, the median age of
this sample was 59 years (IQR, 50, 68), the
median Charlson Comorbidity and APACHE II
scores were 3 (1, 5) and 17 (11, 23), respectively.
The majority were male sex (64.8%), African
American (78.9%) and were admitted from
home (72.5%). The most common comorbidities were diabetes (38.9%), chronic kidney disease (35.0%), and chronic dialysis (25.3%).
More than one-third were hospitalized for at
least 48 h within the past 90 days (38.2%). Most
common sources of BSI were skin and soft tissue
infections (21.7%), followed by infective endocarditis (19.4%) and bone and joint infections
(17.9%).
The majority of patients were on CT therapy
[n = 444 (74.4%)] and a quarter of the patients
received MT [n = 153 (25.6%)]. A comparison of
baseline characteristics between these two
groups is provided in Table 1. No MRSA BSI
patients with pneumonia as a source were
treated with DAP in either cohort arms. The two
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Table 1 Bivariate comparison of clinical characteristics and outcomes of patients managed with monotherapy versus
combination therapy
Characteristicsa

Monotherapy (VAN/
DAP)
(n = 153)

Combination therapy VAN or DAP 1 b- P value
lactam
(n = 444)

56.7 (15.7)

59.3 (16.1)

Demographics
Age in years, mean (± SD)

0.079

Age over 60 years, n (%)

49 (32.0)

199 (44.8)

0.006

Male sex, n (%)

99 (64.7)

288 (64.9)

0.972

128 (83.7)

343 (77.3)

0.094

Caucasian

21 (13.7)

90 (20.3)

0.073

Hispanic

2 (1.3)

4 (0.9)

0.664

Other/unknown

2 (1.3)

5 (0.01)

0.858

Home

117 (76.5)

316 (71.2)

0.205

Nursing facility

25 (16.4)

102 (23.0)

0.084

Transfer from outside institution

11 (7.2)

26 (5.8)

0.555

Pneumonia/LRT

8 (5.2)

98 (22.1)

\ 0.001

Skin/soft tissue

24 (15.7)

55 (12.4)

0.299

Intra-abdominal

0 (0)

4 (0.9)

0.239

Infective endocarditis

28 (18.3)

98 (22.0)

0.682

Intravenous catheter

28 (17.9)

77 (17.3)

0.904

Race, n (%)
African American

Admission source, n (%)

Primary BSI source, n (%)

Bone and joint

40 (26.1)

62 (14.0)

0.001

Prosthetic device

11 (7.2)

22 (5)

0.297

Urinary

3 (2)

10 (2.3)

0.831

CNS

6 (3.9)

6 (1.4)

0.051

Others or unknown

26 (17.0)

81 (18.2)

0.728

Myocardial infarction

6 (3.9%)

37 (8.3)

0.069

Chronic pulmonary diseaseb

25 (16.3)

94 (21.2)

0.197

Dementia

10 (6.5)

51 (11.49)

0.081

Diabetes

57 (37.3)

175 (39.4)

0.637

With end organ damagec

44 (28.8)

124 (27.9)

0.844

Peripheral vascular disease

32 (20.5)

79 (17.8)

0.497

Comorbid conditions, n (%)

CVA (stroke or TIA)

21 (13.7)

75 (16.9)

0.358

Heart failure

31 (20.3)

94 (21.2)

0.811

Moderate to severe CKDd

47 (30.7)

162 (36.5)

0.197

38 (24.8)

113 (25.5)

0.880

HIV

7 (4.6)

13 (2.9)

0.348

AIDS

3 (1.9)

3 (0.6)

0.169

Any immunosuppression factor

11 (7.2)

22 (5)

0.297

Liver disease

30 (19.6)

52 (11.7)

0.014

2 (1.3)

9 (2.0)

0.568

Chronic dialysis

Moderate/severe

e
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Table 1 continued
Characteristicsa

Monotherapy (VAN/
DAP)(n = 153)

Combination therapy VAN or DAP 1 b- P value
lactam(n = 444)

Person with injection drug use

31 (20.3)

68 (15.3)

Prior hospitalization [ 48 in preceding 90 days

54 (35.3)

174 (39.2)

0.392

Prior surgery 30 days preceding index culture

16 (10.3)

29 (6.5)

0.113

Prior MRSA infection B 365 days preceding index 34 (22.2)
culture

54 (12.2)

0.002

Prior antibiotics C 24 h in preceding 90 days

150 (33.8)

0.232

MRSA BSI risk factors, n (%)

60 (39.2)

0.195

Severity of illness factors
APACHE II score, mean [± SD)

13.7 (7.2)

19.1 (9.2)

\ 0.001

ICU at index culture, n (%)

15 (9.8)

78 (17.6)

0.022

CCI score, mean [± SD)

3.1 (2.4)

3.1 (2.4)

0.561

Cefepime

N/A

204 (45.9)

NA

Cefazolin

N/A

149 (33.6)

NA

b-lactam

Ceftaroline

NA

54 (12.2)

NA

Piperacillin/tazobactam

NA

68 (15.3)

NA

Ceftriaxone

NA

85 (15.3)

NA

Ampicillin/sulbactam

NA

14 (3.2)

NA

Meropenem

NA

28 (6.3)

NA

Othersf

NA

7 (1.6)

NA

VAN only

83 (54.2)

258 (58.1)

0.405

DAP only

10 (6.5)

11 (2.5)

0.019

VAN and DAPg

60 (39.2)

175 (39.4)

0.965

Duration of VAN, days, median (IQR)

6.1 (4.4–11.0)

6.0 (4.3–9.2)

\ 0.001

Glycopeptide/lipopeptide

Duration of DAP, days, median (IQR)

10.2 (7.3–15.3)

8.5 (6.0–14.4)

0.021

Removable source of infection

81 (52.9)

180 (40.5)

0.009

ID consult

130 (85.0)

391 (88.1)

0.322

Daptomycin dose, mg
6–8 mg per day

17 (24.3)

62 (33.3)

0.162

8–10 mg per day

29 (41.4)

68 (36.6)

0.493

[ 10 mg per day

17 (24.3)

38 (20.4)

0.516

Clinical outcomes
Clinical failure

80 (52.3)

195 (43.9)

0.073

30-day mortality

14 (9.2)

67 (15.1)

0.064

60-day recurrence

22 (14.4)

39 (8.8)

0.049

Persistent bacteremiah

59 (40.0)

118 (27.5)

0.005

BSI duration, days, median (IQR)

4.2 (2.5–7.5)

3.3 (2.0–5.3)

0.003

Length of stay, days, median (IQR)

12 (8–19)

10 (7–16)

0.087

60-day readmission

62 (40.5)

149 (33.6)

0.134

Safety
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Table 1 continued
Characteristicsa

Monotherapy (VAN/
DAP)(n = 153)

Combination therapy VAN or DAP 1 b- P value
lactam(n = 444)

NephrotoxicityI

22 (14.4)

63 (14.2)

0.954

Thrombocytopenia

21 (13.7)

75 (16.9)

0.358

Clostridium difﬁcile Diarrheaj

4 (2.6)

18 (4.0)

0.415

AIDS acquired immune deﬁciency virus, APACHE II acute physiology and chronic health evaluation II, BSI blood stream infection, CCI
charlson comorbidity score, CNS central nervous system, HIV human immunodeﬁciency syndrome, ID infectious diseases, ICU intensive
care unit, BSI bloodstream infection, LRT lower respiratory tract infection, MIC minimum inhibitory concentration, MRSA methicillinresistant Staphylococcus aureus
a
All values represent number (%) or median (interquartile range)
b
Asthma and chronic obstructive pulmonary disease
c
End-organ damage includes diabetic nephropathy, neuropathy, and retinopathy
d
Chronic kidney disease stages III–IV
e
Moderate/severe liver disease deﬁned as portal hypertension or cirrhosis
f
Other b-lactams may include other carbapenems, monobactams and cephalosporins
g
Patients may have been treated with vancomycin followed by daptomycin during the same treatment course
h
Denominator have changed as patients experiencing mortality before blood stream infection clearance were amended; combination
therapy (n = 429) and monotherapy (n = 148)
I
Nephrotoxicity deﬁned as serum creatinine increase of 0.5 mg/L and 50% from baseline on two consecutive measurements from initial
antibiotic exposure to 72 h after the last dose
j
Clostridioides difﬁcile infection deﬁned as signs/symptoms of infection with positive laboratory test at least 48 h after the initiation of
study antibiotics

groups were similar in general with a few
notable differences. The CT group had a greater
proportion of patients [ 60 years old, admitted
from a nursing home, with pneumonia, endocarditis or primary bacteremia as a source, and
had higher APACHE II scores. The MT group
had a greater proportion of patients with a
MRSA infection history, recent antibiotic usage,
and bone/joint or skin and soft tissue as a bacteremia source. Various BL agents were utilized
in the CT group with the most common being
cefepime 204 (45.9%), followed by cefazolin
149 (33.6%) and ceftaroline 54 (12.2%). Most
patients received an infectious diseases (ID)
service consult; 88.1% and 85.0% in the MT and
CT groups, respectively. Source control was
more commonly pursued in the MT (52.9%)
group compared to CT (40.5%). Median (IQR)
BSI duration was significantly longer in the MT
compared to CT group; 4.2 and 3.3 days,
respectively (P \ 0.003). Median (IQR) length of
stay was also longer but not statistically significant in the MT group compared to CT; 12 (8,
19) and 10 (7, 16) days, respectively (P = 0.087).
A total of 275 (46.1%) study patients experienced composite clinical failure; specifically
80 (52.3%) in the MT group compared to the CT

195 (43.9%) group (unadjusted P = 0.073).
Bivariate analysis was conducted between cases
that achieved clinical success and clinical failure, the results of the analysis are provided in
Table 2. Two components of the composite
endpoint were lower in the CT group: 60-day
recurrence 8.7% versus 14.4% (P = 0.049) and
PB 28.3% versus 41.8% (P = 0.002). On the
other hand, 30-day mortality favored MT 9.2%
versus 15.0%, however; that was not statistically
significant (P = 0.064) (Fig. 2).
Results of the multivariable logistic regression analysis for independent predictors of the
composite endpoint are illustrated in Table 3.
Upon adjusting for the following variables:
age [ 60 years, APACHE II scores, admission
from home, chronic kidney disease, MRSA risks
(surgery within past 30 days and MRSA within
365 days), sources (endocarditis, skin and soft
tissue infection, prosthetic device source). CT
was independently associated with lower odds
of clinical failure [adjusted odds ratio (aOR),
0.545;
95%
confidence
interval
(CI),
0.364–0.817]. Because PB was the primary driver
for the clinical outcome, we also performed a
logistic regression analysis with PB as the
dependent variable and adjusted for sources
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Table 2 Clinical characteristics of patients with clinical failure and no clinical failure
Characteristicsa

Clinical failure
(n = 275)

No clinical failure
(n = 322)

P value

Demographics and comorbid conditions present on admission
Mean age, years (± SD)

59.9 (15.8)

57.6 (16.2)

0.079

Age over 60, years

126 (45.8)

122 (37.9)

0.050

No. of male participants (%)

178 (64.7)

209 (64.9)

0.963

Admission from home

189 (68.7)

244 (75.7)

0.054

Admission from nursing

66 (24.0)

61 (18.9)

0.132

Transfer from outside institution

20 (7.3)

17 (5.2)

0.314

Pneumonia/other lower respiratory tract

55 (20.0)

51 (15.8)

0.185

Skin/soft tissue

19 (6.9)

60 (18.6)

\ 0.001

Infective endocarditis

79 (28.7)

37 (11.5)

\ 0.001

8 (2.9)

4 (1.2)

0.148

Bone and joint

52 (18.9)

50 (15.5)

0.274

Prosthetic device

21 (7.6)

12 (3.7)

0.037

5 (1.8)

8 (2.5)

0.578

45 (16.4)

62 (19.3)

0.359

19 (6.9)

24 (7.5)

0.798

62 (22.5)

63 (19.6)

0.372

52 (18.9)

67 (20.8)

0.563

Dementia

31 (11.3)

30 (9.3)

0.432

Diabetes

112 (40.7)

120 (37.3)

0.388

Peripheral vascular disease

56 (20.4)

54 (16.8)

0.259

CVA (stroke or TIA)

40 (14.5)

56 (17.4)

0.345

109 (39.6)

100 (31.1)

0.028

72 (26.2)

79 (24.5)

0.664

5 (1.8)

15 (4.6)

0.055

Any immunosuppression

13 (4.7)

20 (6.2)

0.429

Liver disease

41 (14.9)

41 (12.7)

0.441

57 (20.7)

42 (13.0)

0.012

108 (39.3)

120 (37.3)

0.615

Primary BSI source

Central nervous system

Urinary
Other or unknown
Comorbidity conditions, no. of patients (%)
Myocardial infarction
Heart failure
Chronic pulmonary disease

Moderate to severe CKD

b

c

Chronic dialysis
HIV

MRSA bacteremia risk factors, no. of patients (%)
Intravenous drug use
Prior hospitalization [ 48 in preceding 90 days
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Table 2 continued
Characteristicsa

Clinical failure
(n = 275)

No clinical failure
(n = 322)

P value

Prior surgery 30 days preceding index culture

16 (5.8)

29 (9.0)

0.141

Prior MRSA infection B 365 days preceding index culture

48 (17.5)

40 (12.4)

0.084

Prior antibiotics C 24 in preceding 90 days

94 (34.2)

116 (36.0)

0.618

Severity of illness markers
APACHE II score, (± SD)
ICU at index culture, n (%)
Charlson Comorbidity score, (± SD)

19.29 (9.6)
49 (17.8)
3.26 (2.4)

16.32 (8.3)
44 (13.7)
2.92 (2.3)

\ 0.001
0.163
0.087

Daptomycin dose, mg
6–8 mg per day

37 (30.1)

42 (31.1)

0.927

8–10 mg per day

42 (34.7)

55 (40.7)

0.321

[ 10 mg per day

27 (22.3)

28 (20.7)

0.760

Removable source of infection

121 (44.0)

140 (43.5)

0.893

ID consult

239 (86.9)

281 (87.6)

0.807

Source control, no. of patients (%)

AIDS acquired immune deﬁciency virus, APACHE II acute physiology and chronic health evaluation II, BSI blood stream
infection, CCI charlson comorbidity score, CNS central nervous system, ID infectious diseases, ICU intensive care unit, BSI
bloodstream infection, MIC minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus, HIV
acquired immunodeﬁciency syndrome
a
All values represent number (%) or median (interquartile range) as indicated
b
Asthma and chronic obstructive pulmonary disease
c
Chronic kidney disease stages III–IV

(endocarditis, pneumonia, bone and joint,
invasive prosthetic device), source control, and
comorbid condition of connective tissue disease. CT was independently associated with
reduced odds of PB (aOR, 0.597; 95% CI,
0.393–0.907). We provide the results of the
model in Table 4.
We did not observe a difference in nephrotoxicity between the CT and MT groups 14.2%
and 14.4%, respectively (P = 0.954). Among
subjects who were on VAN only, nephrotoxicity
was comparable between CT and MT patients;
10.1% and 15.6%, respectively (P = 0.164). No
differences in other secondary safety outcomes
such as thrombocytopenia, rhabdomyolysis and

Clostridioides difficile-associated diarrhea were
observed between the two groups.

DISCUSSION
In response to emerging evidence regarding the
synergy between BL and VAN/DAP in MRSA BSI
treatment, we aimed to explore the association
between BL combination with VAN or DAP
[8–11, 13–15, 19, 22, 24–26]. Our findings support what has been demonstrated in vitro and
in vivo, suggesting that the addition of BL to
VAN/DAP therapy within 72 h for at least 24 h
increases the odds of clinical success. Favorable
clinical outcomes occurred in the CT group
even upon adjustment for all confounding
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Fig. 2 Comparison of clinical outcomes between monotherapy and combination therapy patients. DAP daptomycin, Van
vancomycin
variables in the multivariable regression model.
Interestingly, the clinical success was primarily
driven by significant reductions in 60-day
recurrence and shorter BSI duration (\ 5 days).
BL addition to VAN/DAP has been shown to
have a significant impact on BSI duration
compared with MT, with some influence on the
rate of composite clinical outcomes such as
mortality, relapse, and/or change in antibiotic
therapy during treatment [8, 16, 26, 36–38].
Specifically, median duration of bacteremia had
been reduced from 4 to 3 days when BL were
used with VAN, and from 2.8 to 2.3 days when
BL were used with DAP [8, 26]. Notably, our
definition for PB at a 5-day cut-off has prevented us from comparing our results to other
studies that have used other definitions such as
3 days and 7 days. In other observational studies, ceftaroline when used as salvage therapy in
addition to DAP decreased the duration of bacteremia from 10 to 2 days [36]. In another
study, reduction in BSI duration was more profound when ceftaroline was used with DAP than
DAP MT 4.8 days versus 9.3 days, respectively
[27]. However, statistically significant mortality
differences were not observed between the two
treatment groups. Notably, CT patients had a
higher APACHE II score, intensive care unit
(ICU) encounter, were more likely to be

admitted from nursing facilities and had BSI
sources commonly associated with high mortality (i.e., pneumonia/LRT and infective endocarditis). This further complicates the
conflicting evidence in regard to survival benefits with BL combination therapy particularly
with
rapid
bacterial
eradication
[8, 9, 16, 25, 37, 38].
In our study, CT subjects had higher severity
of illness and more complex infections than MT
subjects, and were therefore at a high risk for
mortality. As demonstrated in previous studies,
high-risk MRSA BSI patients benefit the most
from CT when administered early in the treatment course (i.e., within 72 h) [8, 36, 39]. This
underscores the importance of early BL addition
to achieve timely bacterial eradication (i.e., 3–4 days) and hence avoiding the ‘‘perfect storm’’
[29]. The actual impact of timely bacterial
eradication on mortality is well studied but not
yet definitive [38].
The majority of BLs were administered as
part of empiric treatment and not for targeted
synergy against MRSA. Nevertheless, our CT
group represents a heterogeneous group of BL
agents administered within the initial 72 h of
VAN/DAP initiation. Nephrotoxicity and other
safety outcomes were similar between both
groups, and remarkably comparable to previous
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Table 3 Multivariable logistic regression model for factors independently associated with clinical failure
Variable

Unadjusted odd ratio
(95% CI)

Adjusted odds ratio
(95% CI)

Endocarditis

3.369 (2.127–5.336)

3.294 (2.115–5.132)

Skin and soft tissue

0.775 (0.499–1.203)

Prosthetic device

1.746 (0.796–3.829)

Pneumonia

1.434 (0.884–2.326)

Source

Co-morbidity
CKD

1.190 (0.807–1.754)

Prior MRSA in 365 days

1.566 (0.956–2.563)

Prior surgery in 365 days

0.716 (0.365–1.406)

1.545 (0.954–2.500)

Other factors
Admission, home

0.775 (0.521–1.154)

Age [ 60 years

1.222 (0.844–1.769)

APACHE II score

1.034 (1.011–1.058)

1.045 (1.029–1.072)

0.539 (0.356–0.816)

0.545 (0.364–0.817)

Treatment
Combination therapy

Hosmer–Lemeshow goodness of ﬁt test P = 0.983; variance inﬂation factor = 1.0–1.5 for all variables included at model
entry
APACHE II acute physiology and chronic health evaluation II, CKD chronic kidney disease

studies [16, 40]. Notably, because our study
includes VAN- and DAP-treated patients, it may
reduce our ability to detect VAN-associated
nephrotoxicity. Because our institutions avoid
piperacillin-tazobactam/VAN combinations and
utilize cefepime/VAN instead, due to the wellknown association with nephrotoxicity, only a
small proportion of CT patients in our study
have received piperacillin-tazobactam, and
most did in combination with DAP [28]. This
may have contributed to the lower nephrotoxicity rates observed in our cohort, which is
crucial, particularly in the light of the CAMERA2 study where higher nephrotoxicity had been
observed when VAN was used in combination
with flucloxacillin.
To our knowledge, this is the largest realworld study to date comparing clinical outcomes in MRSA BSI patients receiving VAN/DAP

MT to VAN/DAP CT with BL. Strengths of this
study include a specific definition of BL exposure with regards to VAN/DAP timing, exclusion
of patients who have not had a follow-up blood
culture, robust sample size captured in over
12 years duration, and findings that are confirmatory of previously published data in CT for
MRSA BSI [8, 25, 26].
When interpreting these findings, there are
several considerations to note. First, although
this was a multi-hospital site study, it was
restricted to hospitals within a single healthcare system in the Detroit area. Therefore, it
may be challenging to generalize these findings
to other patient populations with different
demographics and clinical practice patterns.
These hospitals, as of 2016, have mandated an
infectious disease consult for all MRSA-positive
blood cultures, which may have had an impact
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Table 4 Multivariable logistic regression for factors independently associated with persistent bacteremia
Variable

Unadjusted odd ratio
(95% CI)

Adjusted odds ratio
(95% CI)

Endocarditis

3.342 (2.128–5.247)

3.331 (2.132–5.205)

Skin and soft tissue

0.639 (0.396–1.032)

0.629 (0.391–1.014)

Pneumonia

0.597 (0.317–1.124)

Bone and joint

1.488 (0.921–2.406)

Prosthetic device

1.366 (0.614–3.040)

Source

1.517 (0.943–2.440)

Other factors
Source control

1.236 (0.828–1.844)

Treatment
Combination therapy

0.604 (0.397–0.918)

0.597 (0.393–0.907)

Hosmer–Lemeshow goodness of ﬁt test P = 0.980; variance inﬂation factor = 1.0–1.27 for all variables included at model
entry
on the clinical outcomes. Second, because this
was a retrospective study, results may be challenged by inherent limitations associated with
this study design and unmeasured confounders.
Recognizing this limitation, objective and
measurable outcomes were selected (i.e., blood
culture clearance and 30-day mortality). Furthermore, the MT arm was predominately treated with VAN or VAN followed by DAP and not
DAP alone: 54.2%, 39.2%, and 6.5%, respectively. Despite that these two agents are similar
in many aspects including spectrum of activity,
these two antibiotics are not equivalent and,
therefore, our results may be more generalizable
to VAN or VAN/DAP rather than DAP alone.
Additionally, it was not possible to account for
VAN exposure in the entire cohort since the
area under the curve (AUC) monitoring strategy
was initiated within the last 4 years of the study
period [41]. However, it is unlikely that this
small proportion of patients have impacted the
composite endpoint, as VAN exposure using
AUC monitoring is a known factor to influence
VAN safety outcomes rather than clinical outcomes [42]. Moreover, although ceftaroline was
the BL of choice for only a small proportion of
CT patients (12%); ceftaroline is the only BL
available in the United States to date with

in vitro MRSA activity providing known synergy
particularly with DAP [22]. This may have had
an indirect impact on PB rates within the CT
group. However, it remains unclear if MT with
ceftaroline alone would be superior to MT with
VAN/DAP or even CT with BL. Finally, because
our study evaluates a diverse group of BLs with
diverse therapeutic characteristics, it is challenging to draw specific conclusions with regard
to which specific BL is preferred when considering CT for MRSA BSI treatment.

CONCLUSION
We found that BL given B 72 h of VAN/DAP
therapy improves composite clinical outcomes
for patients with MRSA BSI and that CT was well
tolerated compared to MT alone. Time to bacterial clearance was shorter in patients managed
with CT compared to MT. These data add to the
evidence suggesting that CT may improve
overall patient outcomes and should be further
investigated to ascertain its role in MRSA BSI
treatment. Additional studies, particularly
prospective analysis, are warranted to explore
the relationship between BL selection in CT and
clinical benefit.
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